A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Neuphoria Therapeutics Inc.
NEUP
$12M
Mkt Cap
$3.64
-7.14%
Neuphoria Therapeutics Inc. (NEUP) has a 5-year average return on invested capital (ROIC) of -7.3%. This is below average and may indicate limited pricing power.
Neuphoria Therapeutics Inc. (NEUP) has a market capitalization of $20M. It is classified as a small-cap stock.
Neuphoria Therapeutics Inc. (NEUP) does not currently pay a regular dividend.
Neuphoria Therapeutics Inc. (NEUP) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Neuphoria Therapeutics Inc. (NEUP) reported annual revenue of $16 million in its most recent fiscal year, based on SEC EDGAR filings.
Neuphoria Therapeutics Inc. (NEUP) has a net profit margin of -2.4%. The company is currently unprofitable.
Neuphoria Therapeutics Inc. (NEUP) generated $77 thousand in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
We are a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine ("ACh") receptor ("a7 receptor") for the acute, “as needed” treatment of social anxiety disorder (“SAD”) and for chronic treatment of post-traumatic stress disorder (“PTSD”). There remains a significant unmet medical need for the over 27 million patients in the United States alone suffering from SAD and PTSD. BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co.
| Metric | TTM | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 16M | - | - | - | - |
| Net Income | -5.7M | -370K | -21M | -22M | -8.7M | -7.1M |
| EPS | $-1.08 | $-0.12 | $-0.01 | $-0.01 | $-0.00 | $-0.00 |
| Free Cash Flow | 0 | 77K | -15M | -22M | -7.5M | -3.9M |
| ROIC | -7.7% | -2.0% | -69.8% | 33.0% | 9.6% | - |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.50 | 0.30 | 0.21 | 0.14 | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -3.6M | -1.1M | -22M | 5.8M | 1.3M | 3.3M |
| Operating Margin | 0.0% | -7.2% | - | - | - | - |
| ROE | -19.1% | -2.0% | -69.8% | -50.1% | -28.9% | - |
| Shares Outstanding | 5M | 3M | 4,276M | 4,352M | 3,479M | 2,847M |
| Metric | 2020 | 2021 | ||||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | N/A | N/A | 16M | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 5.8M | 5.8M | 16M | 13M | 9.0M | 9.9M |
| SG&A | N/A | N/A | N/A | 8.9M | 7.8M | 7.5M |
| EBIT | 3.3M | 1.3M | 5.8M | -22M | -1.1M | -3.6M |
| Op. Margin | N/A | N/A | N/A | N/A | -7.2% | 0.0% |
| Net Income | -7.1M | -8.7M | -22M | -21M | -370K | -5.7M |
| Net Margin | N/A | N/A | N/A | N/A | -2.4% | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | N/A | 9.6% | 33.0% | -69.8% | -2.0% | -7.7% |
| ROE | N/A | -28.9% | -50.1% | -69.8% | -2.0% | -19.1% |
| ROA | -2041.0% | -31.9% | -36.4% | -45.6% | -1.3% | -15.5% |
| Cash Flow | ||||||
| Op. Cash Flow | -3.9M | -7.5M | -22M | -15M | 77K | -2.4M |
| Free Cash Flow | -3.9M | -7.5M | -22M | -15M | 77K | 0 |
| Owner Earnings | -6.3M | -9.2M | -102M | -17M | -749K | -3.3M |
| CapEx | 8K | 1K | 2K | 0 | 0 | 0 |
| Maint. CapEx | 2.4M | 1.7M | 1.1M | 663K | 663K | 663K |
| Growth CapEx | 0 | 0 | 0 | N/A | N/A | 0 |
| D&A | 2.4M | 1.7M | 1.1M | 663K | 663K | 663K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | N/A | N/A | 79M | 1.3M | 164K | 323K |
| Debt Repayment | 7.5M | 11M | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -44M |
| Cash & Equiv. | 4.6M | 28M | 23M | 12M | 14M | 44M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | 0.14 | 0.21 | 0.30 | 0.50 | 0.00 |
| Interest Coverage | 2.8 | 2.1 | 215.8 | -1033.1 | -64.8 | -64.8 |
| Equity | N/A | 48M | 39M | 22M | 19M | 30M |
| Total Assets | 349K | 54M | 65M | 29M | 29M | 37M |
| Total Liabilities | N/A | 6.7M | 8.4M | 6.6M | 9.6M | 6.9M |
| Intangibles | N/A | N/A | 0 | 6.1M | 4.8M | 13M |
| Retained Earnings | N/A | N/A | N/A | -162M | -178M | -186M |
| Working Capital | N/A | 29M | 38M | 11M | 11M | 21M |
| Current Assets | N/A | 31M | 42M | 13M | 15M | 23M |
| Current Liabilities | N/A | 2.4M | 3.4M | 2.7M | 4.2M | 2.6M |
| Per Share Data | ||||||
| EPS | -0.00 | -0.00 | -0.01 | -0.01 | -0.12 | -1.08 |
| Owner EPS | -0.00 | -0.00 | -0.02 | -0.00 | -0.23 | -0.62 |
| Book Value | N/A | 0.01 | 0.01 | 0.01 | 5.91 | 5.51 |
| Cash Flow/Share | -0.00 | -0.00 | -0.00 | -0.00 | 0.02 | -0.93 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 2.8B | 3.5B | 4.4B | 4.3B | 3.2M | 5.4M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -3.4 |
| P/FCF | N/A | N/A | N/A | N/A | 291.3 | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 149.1 | 99.0 | 0.6 | 0.7 |
| Price/Sales | N/A | N/A | N/A | N/A | 0.6 | N/A |
| FCF Yield | N/A | N/A | -0.3% | -0.4% | 0.7% | N/A |
| Market Cap | N/A | N/A | 8.5B | 3.3B | 11M | 20M |
| Avg. Price | N/A | N/A | 114.34 | 62.28 | 5.50 | 3.64 |
| Year-End Price | N/A | N/A | 93.60 | 24.72 | 7.00 | 3.64 |
Neuphoria Therapeutics Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Neuphoria Therapeutics Inc. (NEUP) has a debt-to-equity ratio of 0.50. This indicates moderate leverage.
Neuphoria Therapeutics Inc. (NEUP) reported earnings per share (EPS) of $-0.12 in its most recent fiscal year.
Neuphoria Therapeutics Inc. (NEUP) has a return on equity (ROE) of -2.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for Neuphoria Therapeutics Inc. (NEUP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Neuphoria Therapeutics Inc. (NEUP) has a book value per share of $5.91, based on its most recent annual SEC filing.